Skip to NavigationSkip to content

UCB’s Kola joins Astex board

Published on: 05/06/10

Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics.

Astex's non-executive chairman Peter Fellner said: “I am delighted that Ismail has decided to join Astex's Board at this time in the company's development. With three of our products about to enter into phase II clinical trials, Ismail's exceptionally broad experience in pharmaceutical research and development will be an enormous asset to Astex as we continue to capture the value of the company's technology and products going forward.”

Dr Kola is currently president of new medicines at UCB, having joined the Belgium pharma company from Schering-Plough in November 1999.

At Schering-Plough he served as senior VP of discovery research and early clinical research and experimental medicine and prior to this held senior positions at Merck and Pharmacia (now part of Pfizer).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches